著者: MesalamAhmed Atef, VercauterenKoen, MeulemanPhilip

原題: Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance.

著者: KheloufiFarid, BellissantEric, CotteLaurent, Poizot-MartinIsabelle, QuarantaSylvie, GarraffoRodolphe, Barrail-TranAurélie, RenaultAlain, FournierIsabelle, LacarelleBruno, BourlièreMarc, MolinaJean-Michel, SolasCaroline,

原題: Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.

著者: ŞanlıdağTamer, SayanMurat, AkçalıSinem, KasapElmas, BuranTahir, ArıkanAyşe

原題: [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].

著者: HartmanJoshua, BichoupanKian, PatelNeal, ChekuriSweta, HartyAlyson, DieterichDouglas, PerumalswamiPonni, BranchAndrea D

原題: Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.

著者: Sargin AltunokElif, SayanMurat, AkhanSila, AygenBilgehan, YildizOrhan, Tekin KorukSuda, MistikResit, DemirturkNese, UralOnur, KoseŞükran, AyniogluAynur, KorkmazFatime, ErsozGülden, TunaNazan, AyazCelal, KarakeciliFaruk, KetenDerya, InanDilara, YaziciSaadet, KoculuSafiye, YildirmakTaner

原題: Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C.

著者: DietzJulia, RuppDaniel, SusserSimone, VermehrenJohannes, PeifferKai-Henrik, FilmannNatalie, BonDimitra, KuntzenThomas, MaussStefan, GrammatikosGeorgios, PernerDany, BerkowskiCaterina, HerrmannEva, ZeuzemStefan, BartenschlagerRalf, SarrazinChristoph

原題: Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.

著者: CostaVanessa Duarte, DelvauxNathália, Brandão-MelloCarlos Eduardo, NunesEstevão Portela, de SousaPaulo Sérgio Fonseca, de Souza RodriguesLia Laura Lewis Ximenez, LampeElisabeth, do Amaral MelloFrancisco Campello

原題: Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1.

著者: SegecAndrej, SlatteryJim, MoralesDaniel R, JanuskieneJustina, KurzXavier, ArlettPeter

原題: Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data.

著者: BatskikhS N, KarandashovaI V, NeverovA D, ChulanovV P

原題: [Resistance to protease inhibitors and efficiency of antiviral therapy in patients with chronic hepatitis C].

著者: MarascioNadia, PaviaGrazia, StrazzullaAlessio, DierckxTim, CuypersLize, VranckenBram, BarrecaGiorgio Settimo, MiranteTeresa, MalangaDonatella, OliveiraDuarte Mendes, VandammeAnne-Mieke, TortiCarlo, LibertoMaria Carla, FocàAlfredo,

原題: Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients.

著者: AroojMahreen, ShehadiIhsan, NassabChahlaa N, MohamedAhmed A

原題: Computational insights into binding mechanism of drugs as potential inhibitors against SARS-CoV-2 targets.

著者: MohamedKawthar, YazdanpanahNiloufar, SaghazadehAmene, RezaeiNima

原題: Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.

著者: SenínAlicia, BroquetasTeresa, CañeteNuria, LensSabela, LondoñoMaría-Carlota, FerraroMariana, FornsXavier, SalarAntonio, CarriónJose A

原題: Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment.

著者: MukhametovAzat

原題: Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease.

著者: Poizot-MartinIsabelle, BellissantEric, GarraffoRodolphe, ColsonPhilippe, PirothLionel, SolasCaroline, RenaultAlain, BourlièreMarc, HalfonPhilippe, GhosnJade, AlricLaurent, NaqviAlissa, CarrieriPatrizia, MolinaJean-Michel,

原題: Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.

著者: LibertiAlfonso, RaddiAdriana, CuomoNunzia

原題: Genotypic analysis of HCV 1a by sequencing of the NS3 proteasic region in simeprevir therapy candidates.

著者: StahmeyerJona T, RossolSiegbert, BertFlorian, BökerKlaus H W, BruchHarald-Robert, EisenbachChristoph, LinkRalph, JohnChristine, MaussStefan, HeyneRenate, SchottEckart, Pfeiffer-VornkahlHeike, HüppeDietrich, KrauthChristian

原題: Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.

著者: Nazario de MoraesLeonardo, Tommasini GrottoRejane Maria, Targino ValenteGuilherme, de Carvalho SampaioHeloisa, MagroAngelo José, FogaçaLauana, WolfIvan Rodrigo, PerahiaDavid, Faria SilvaGiovanni, Plana SimõesRafael

原題: A novel molecular mechanism to explain mutations of the HCV protease associated with resistance against covalently bound inhibitors.

著者: LangnessJacob A, TabanoDavid, WielandAmanda, TiseSarah, PrattLindsay, HarringtonLauren Ayres, LinSonia, GhuschcyanVahram, NairKavita V, EversonGregory T

原題: Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.

著者: Ben YakovGil, MontanoDaniela, Abu FrehaNaim, EtzionOhad, DizingofVitaly, MushkaloAlex, ShwartsDoron, MonitinShulamit, TakchickAnna, ZilbermanDorin, SikulerEmanuel, FichAlexander

原題: [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].

著者: PerišićOgnjen

原題: Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.

著者: DinuSorin, CalistruPetre-Iacob, CeauşuEmanoil, TârdeilGraţiela, OprişanGabriela

原題: SCREENING OF PROTEASE INHIBITORS RESISTANCE MUTATIONS IN HEPATITIS C VIRUS ISOLATES INFECTING ROMANIAN PATIENTS UNEXPOSED TO TRIPLE THERAPY.

著者: DavitkovPerica, ChandarApoorva Krishna, HirschAmy, CompanAnita, SilveiraMarina G, AnthonyDonald D, SmithSuzanne, GideonClare, BonomoRobert A, Falck-YtterYngve

原題: Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C.

著者: SalmonD, Bani-SadrF, GilbertC, RosenthalE, ValantinM A, SimonA, NeauD, MorlatP, LokoM A, WittkopL, DabisF,

原題: HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.